Nektar Therapeutics (NKTR) Offers Additional Detail on Bristol-Myers Squibb Collaboration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb
September 27, 2016 7:45 AM EDTSAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with Bristol-Myers Squibb. The call will begin at 9:00 a.m. Eastern Time (ET)/6:00 a.m. Pacific Time (PT) on Tuesday, September 27, 2016. A live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website at... More
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214
September 27, 2016 6:59 AM EDTNew collaboration will explore the potential benefits of combining Bristol-Myers Squibbs anti-PD-1 antibody with Nektars CD122-biased agonist in five tumor types
SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY)... More
